Aditi Mehta, DO
Atara Biotherapeutics
3
0
0
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (3)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Ming-yuan Chen, MD, PhD
Sun Yat-sen University
Shared therapeutic areas:
Christopher J Melani, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Jun Ma, M.D.
Sun Yat-sen University
Shared therapeutic areas:
Mitchell Cairo, MD
New York Medical College
Shared therapeutic areas:
Helen Heslop, MD
Baylor College of Medicine
Shared therapeutic areas:
Lizhi Niu, PhD
Fuda Cancer Hospital
Shared therapeutic areas:
Nai-Kong V. Cheung, MD, PhD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Lung-Ji Chang, PhD
Shenzhen Geno-Immune Medical Institute
Shared therapeutic areas:
Areej El-Jawahri, MD
Massachusetts General Hospital
Shared therapeutic areas:
Jorge Cortes, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (3)
Showing 3 of 3 trials
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
All 3 trials loaded